Invitrogen Corp., which has been steadily building its cell therapy expertise, announced in mid-May the formation of a separate cell therapy business unit focused on the specific needs of the clinical cell therapy market.
University of Florida researchers have identified a drug compound that may prevent tissue damage associated with cardiovascular disease, according to a study published in the May 1 edition of the American Heart Association journal Hypertension.
News recently out of a discussion at the The Royal Society, London, is raising hopes that an effective and affordable cure for malaria is now on the horizon. But what do both Bill Gates and Chairman Mao have to do with this story? Well, plenty, if you follow the thread and history of malaria treatments.
In times like these, when the pendulum of fear swings to risk avoidance, biopharma can only develop products that meet both customer needs and Wall Street expectations through innovative, novel product development based on a reconsidered approach to risk management.